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Abstract
Background: Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by an
expanded CAG repeat in the HD  gene. Both excitotoxicity and oxidative stress have been
proposed to play important roles in the pathogenesis of HD. Since no effective treatment is
available, this study was designed to explore the therapeutic potential of erythropoietin (EPO), a
cytokine that has been found to prevent excitotoxicity, and to promote neurogenesis. To avoid the
side effects of a raised hematocrit, we used asialoerythropoietin (asialoEPO), a neuroprotective
variant of EPO that lacks erythropoietic effects in mice. R6/2 transgenic HD mice were treated with
this cytokine from five to twelve weeks of age.
Results:  We provide new evidence that cell proliferation in the dentate gyrus of the R6/2
hippocampus is reduced by 50% compared to wild-type littermate controls. However, we found
that the asialoEPO treatment did not affect the progression of motor symptoms, weight loss or the
neuropathological changes. Furthermore, cell proliferation was not enhanced.
Conclusions: We conclude that the chosen protocol of asialoEPO treatment is ineffective in the
R6/2 model of HD. We suggest that reduced hippocampal cell proliferation may be an important
and novel neuropathological featu r e  i n  R 6  HD  mi c e  t h at  c ou l d  b e  as se ss e d  w h e n e v a l ua t i ng
potential therapies.
Background
Huntington's disease (HD) is an autosomal dominant
hereditary disorder caused by the expansion of a CAG
repeat in the HD gene [1]. Affected patients display per-
sonality changes and depression before the onset of
motor symptoms that include chorea and bradykinesia.
Progressive dementia and body weight loss then follow.
Death usually occurs within 15–20 years from the onset of
symptoms. The neuropathology is characterized by the
development of neuronal intranuclear inclusions (NII)
containing huntingtin in a subset of neurons and by neu-
ronal death, particularly in the striatum and cerebral cor-
tex. It is thought that the neurons are dysfunctional for
many years before they finally succumb to the disease [2].
The pathogenetic mechanisms in HD are far from under-
stood, but have been suggested to involve excitotoxicity
and oxidative stress [3] and possibly an impairment of the
ubiquitin proteasome system [4].
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There is still no satisfactory treatment for HD. The R6/2
mouse, that expresses exon 1 of the human HD gene with
an expanded CAG trinucleotide repeat (around 150 CAG
repeats) [5], is the most studied transgenic mouse model
of HD [6]. This model exhibits decreased striatal and total
brain size [5,7], ubiquitinated nuclear and cytoplasmic
inclusion bodies [8], altered levels of neurotransmitters
[9] and their receptors [10], decreased expression of stri-
atal signaling genes [11], and progressive motor [12] and
cognitive deficits [13,14]. There is relatively little, if any,
neuronal death in the brains of R6/2 mice [15,16], but
there is widespread loss of retinal ganglion neurons [17].
Erythropoietin (EPO), originally discovered as kidney-
produced cytokine regulating haematopoiesis, has been
found to enter the brain after peripheral administration,
and to be endowed with potent neuroprotective efficacy.
It has receptors in brain tissue [18,19] and beneficial phar-
macological effects were described in models of focal
ischemia, spinal cord injury, retinal injury, brain trauma
and subarachnoid hemorrhage, and also a human phase
II stroke study [20-27]. Chronic administration of EPO is
linked to the side effects of a dramatically raised hemat-
ocrit. Such side effects are not observed upon use of the
natural EPO metabolite asialoerythropoietin (asia-
loEPO), a molecule that otherwise has the same neuro-
protective potency as EPO in several animal models of
disease [28]. Similar to EPO, asialoEPO has the capacity to
cross the intact blood brain barrier [28]. We were inter-
ested in studying whether stimulation of EPO-related sig-
naling pathways would have beneficial effects in R6/2 HD
mice. We used asialoEPO to selectively trigger the brain
EPO receptor in this chronic dosing study. The cytokine
asialoEPO was administered three times weekly to R6/2
mice from 5 weeks until 12 weeks of age. The effect of the
compound was analyzed with regard to the development
of motor symptoms, weight loss, neuropathology and
impaired cell proliferation. We found that cell prolifera-
tion in the dentate gyrus of the hippocampus, one of the
neurogenic zones in the adult brain, was reduced in R6/2
mice, however the asialoEPO treatment did not exert any
beneficial effects in this HD mouse model.
Results
Administration of asialoEPO does not affect the 
behavioral phenotype in R6/2 mice
Mice were assessed weekly from 5 to 12 weeks of age on
the rotarod (Fig. 1A). There was no significant effect of
asialoEPO on the development of motor deficits in the
R6/2 mice as expressed by reduced time spent on the
rotarod. The mice were also assessed regarding motor
activity in an open field at 10 and 12 weeks of age (Table
1). AsialoEPO did not affect the reduced movement dis-
played by the R6/2 mice at either of these time points.
Mice were assessed weekly with regard to their develop-
ment of a paw clasping behavior. No wild-type mice
showed any signs of clasping. Around 80% of the R6/2
mice in both groups scored one point in clasping at week
7. At week 10, all R6/2 mice scored two points in clasping.
However, asialoEPO treatment had no effect on the clasp-
ing behavior.
No effect of asialoEPO on the loss of body weight
An important symptom in R6/2 mice is lack of the pro-
gressive body weight gain that occurs in wild-type litter-
mates. The weight of the mice was assessed weekly from 5
to 12 weeks of age. AsialoEPO treatment did not affect the
reduced body weight in the R6/2 mice (Fig. 1B).
AsialoEPO treatment does not affect neuropathological 
features in R6/2 mice
The neuropathological characteristics of R6/2 mice
include NIIs of mutant huntingtin, which can be assessed
using the EM48 antibody [29]. All neuropathological
analyses were performed in R6/2 and wild-type mice at
the age of 12 weeks. In the five striatal sections assessed
per mouse, there were around 426000 ± 31000 NIIs in the
vehicle-treated R6/2 mice and 407000 ± 45000 inclusions
in the asialoEPO-treated mice (Student's test, n.s.). The
unilateral striatal volume, assessed in the medial part of
the striatum at the level of the appearance of the posterior
anterior commissure, measured 8.23 ± 0.53 mm3 in wild-
type mice, 5.14 ± 0.21 mm3 in vehicle-treated R6/2 mice
and 5.26 ± 0.07 mm3 in asialoEPO-treated R6/2 mice. A
one-factor analysis of variance (ANOVA) revealed a signif-
icant difference between both R6/2 groups and the wild-
type control group (F (2, 6) = 29.01, p < 0.005 using Bon-
ferroni-Dunn post-hoc test) but no difference between
vehicle-treated and asialoEPO-treated R6/2 mice (p >
0.05). The cross mean sectional area of neurons exhibiting
dopamine and cAMP regulated phosphoprotein of a
molecular weight of 32 kDa (DARPP-32)-immunostain-
ing was 78 ± 6 µm2 in wild-type mice, 55 ± 3 µm2 in vehi-
cle-treated R6/2 mice and 59 ± 1 µm2 in asialoEPO-treated
R6/2 mice. Again, there was a significant difference
between both R6/2 groups and the wild-type group (one
factor ANOVA (F (2, 6) = 9.64, p < 0.05, Bonferroni-Dunn
post hoc test) but no difference between asialoEPO- and
vehicle-treated R6/2 mice (p > 0.05).
Reduced BrdU labeling in R6/2 mouse brains, but no 
increase by asialoEPO administration
We injected bromodeoxyuridine (BrdU) in the R6/2 mice
during the last six days of survival to investigate whether
the proliferation of cells in neurogenic regions of the
brain was altered in R6/2 mice and if asialoEPO would
affect the rate of cell proliferation. BrdU incorporates into
cells undertaking DNA synthesis and therefore labels pro-
liferating cells. Proliferation of neuronal progenitors, i.e.
neurogenesis has been found to occur mainly in theBMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/17
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olfactory bulb, the subependymal layer in the subven-
tricular zone, and in the dentate gyrus of the hippocam-
pus. In the subependymal layer, BrdU labeled cells were
assessed in 5 sections/mouse. In this region, there was
only a trend towards a reduced number of BrdU labeled
cells in R6/2 mice compared to their wild-type littermates
at the age of 12 weeks (Fig. 2A). In the dentate gyrus, we
found that there was a reduced number of BrdU labeled
cells in R6/2 mice compared to the wild-type mice (Fig. 2B
and 3). However, the administration of asialoEPO, which
has been shown to have neurogenic properties [30], was
not able to reverse this. Stereological assessment of the
total number of neuronal nuclei (NeuN)-positive neurons
in the dentate gyrus revealed that there were 117000 ±
15000 neurons in wild-type mice, 142000 ± 5000 neu-
rons in vehicle-treated R6/2 mice and 158000 ± 20000
neurons in asialoEPO-treated R6/2 mice (one factor
ANOVA F (2, 9) = 1.91, p > 0.05).
Discussion
There is still no satisfactory treatment available for HD,
nor are the underlying disease mechanisms known. Exci-
totoxicity and oxidative stress have been suggested to be
involved in the pathogenesis, and administration of EPO
has been shown to be protective against such insults. We
therefore studied whether asialoEPO, an EPO analogue,
exerts beneficial effects in R6/2 HD mice. We injected R6/
2 mice 3 times weekly with asialoEPO from five to twelve
weeks of age, and assessed the effects of the treatment by
analyzing rotarod; paw clasping; general activity in the
open field; body weight; the frequency of striatal hunting-
tin inclusions; cross sectional area of striatal projection
neurons; volume of the striatum; and the number of pro-
liferating cells in two neurogenic brain regions. We did
not detect beneficial effects of the synthetic analogue of
EPO in any of the assessed parameters. However, we did
not measure whether asialoEPO provided neuroprotec-
tion of retinal ganglion cells, which are known to die in
R6/2 mice [17], and future studies to examine this possi-
bility are warranted.
There may be several reasons why asialoEPO did not have
any effect in the R6/2 mice. It has previously been shown
that EPO has neuroprotective effects in acute neurodegen-
erative paradigms, such as hypoxia and ischemia
[20,24,31]. The only study published so far with asia-
loEPO also focused on acute models [28]. However, the
R6/2 model provides a chronic neuropathological model
without any cell death. Moreover, one of the proposed
neuroprotective mechanisms for EPO relies upon a func-
tional transcriptional machinery. EPO is thought to acti-
vate EPO receptors that are linked to the Janus kinase 2
(Jak2) pathway. The activation of this pathway has been
linked to the activation and nuclear translocation of
nuclear factor-kB (NFkB), which once in the nucleus, can
No effect of asialoEPO on the decline in rotarod perform- ance or body weight in R6/2 mice Figure 1
No effect of asialoEPO on the decline in rotarod per-
formance or body weight in R6/2 mice. Mice were 
tested weekly on the rotarod for 3 trials of 180 s each, with 
the speed of 15 rpm. The value of the mean latency to fall for 
these three trials was then compared between the mice. The 
testing began at 5 weeks and continued until 12 weeks of age. 
The data was analyzed using a two factor repeated measures 
ANOVA that revealed a significant difference between the 
groups (F (2, 96) = 16.61, p = 0.0001) and a significant effect 
of time (F (6, 96) = 4.16, p = 0.0009). However, administra-
tion of asialoEPO 3 times weekly from 5 to 12 weeks of age 
did not significantly affect the decline in rotarod performance 
in R6/2 mice (A). The mice were also weighed weekly from 5 
to 12 weeks of age (B). The data were analyzed using a two 
factor repeated measures ANOVA that revealed a significant 
effect of time (F (6, 96) = 1.55, p < 0.0001) and significant dif-
ference in the weight over time between the groups (F (12, 
96) = 1.32, p < 0.0001). However, there was no effect of 
asialoEPO on the progressive reduction in body weight in 
R6/2 mice (F (2, 96) = 1.47, p > 0.05).BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/17
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lead to the up-regulation of neuroprotective genes (e.g.,
the caspase inhibitors: X-linked inhibitor of apoptosis
proteins, XIAP, and cellular inhibitor of apoptosis pro-
teins-2, c-IAP2) [32]. There are several studies showing
transcriptional abnormalities in R6/2 mice [11]. There-
fore, it is possible that EPO can not induce the necessary
up-regulation of neuroprotective genes that would be
needed in order to exert its neuroprotective effect.
Several other compounds have been found to exert mod-
erate ameliorative effects on the behavior and neuropa-
thology of R6/2 mice and increase their survival with up
to 15% [33-36]. Although the pathological events under-
lying the development of a phenotype in the R6/2 mice
are not fully understood, those studies demonstrate that
the mouse model is in principle amenable to therapy.
Adult hippocampal neurogenesis was described already
forty years ago, but it is only recently that this phenome-
non has been accepted fully [37,38]. Proliferation and
maturation of neurons are now known to occur in specific
regions of the adult brain; i.e. the olfactory bulb, the sub-
ependymal layer and the dentate gyrus of the hippocam-
pus. Although the functional impact of adult
neurogenesis is not yet known, it has been suggested to be
involved in important neuronal functions such as learn-
ing and memory. It is a highly dynamic process with a
number of controlling factors and regulators [38-40].
Briefly, it can be upregulated by enriched environment,
exercise, learning, estrogen, antidepressant drugs, electro-
convulsive therapy and delivery of growth factors such as
brain derived neurotrophic factor (BDNF) and insulin
growth factor 1 (IGF1). It is downregulated by stress, glu-
cocorticoids, inflammation, excitotoxicity, opiate intake,
and during aging. The underlying molecular mechanisms
controlling neurogenesis are not fully understood, but
may involve activation of the cAMP response-element
binding protein (CREB) cascade. Neurogenesis in the
adult brain provides a thrilling possibility to manipulate
the endogenous restorative capacity in neurodegenerative
disorders. Also, it is not fully explored if or to what extent
the neurogenic process is altered in neurodegenerative
diseases and whether such changes even may contribute
to the symptomatology [41].
This study is, to the best of our knowledge, the first where
R6/2 HD mice were assessed with regard to BrdU labeling
in neurogenic zones in the brain. By following a protocol
that was aimed to evaluate cell proliferation (i.e., six days
of BrdU injection followed by perfusion of the mice 12 h
after the last injection), we found a reduction of BrdU-
positive cells in the R6/2 dentate gyrus, which is rich in
neurons. In this region, the majority (80%) of the surviv-
ing BrdU-labeled cells are known to mature into neurons
[40]. BrdU is a nucleotide precursor that incorporates into
the DNA of dividing cells, and is commonly used as a
marker of cell genesis. As BrdU is a thymidine analogue, it
could also label cells that are undergoing DNA repair.
However, several experimental data argue against that
being a major contributor to the labeled cells in the den-
tate gyrus. In the dentate gyrus, mitotic cells are present in
the neurogenic zones where BrdU labeling has been
found, BrdU positive cells have been shown to mature
into neurons, irradiation reduces the amount of BrdU
labeling while DNA repair is increased, and no BrdU labe-
ling has been detected in apoptotic cells [42].
The underlying mechanism for the reduced cell prolifera-
tion in the R6/2 mice is not yet known. Recent reports
show that inflammation and microglial activation impair
hippocampal neurogenesis in rats [43,44]. However,
microglia density is decreased and their structural mor-
phology is abnormal already at 7 weeks in R6/2 mice [45],
rendering this theory less likely. Other factors, such as
stress, increased glucocorticoids and an accelerated aging
process could also be involved in reducing cell prolifera-
tion in the R6/2 mice. Alternatively, positive regulators of
neurogenesis could be decreased in the HD mice. Interest-
ingly, BDNF reductions have been found in HD patients
[46] and decreased CREB-mediated transcription has been
described in HD models [47]. However the extent of these
changes are not fully explored in R6/2 mice. Noteworthy
is that the mice in the present study had been subjected to
many weekly injections and behavioral handling, which
Table 1: No effect of asialoEPO on the progressive reduction in activity in R6/2 mice. The activity of the mice was assessed at 10 and 12 
weeks of age in an open field. The open field was divided into 25 equal squares of 5 × 5 cm each. The number of entered squares during 
2 min was assessed as a measure of general activity. The data was analyzed using a two-factor repeated measures ANOVA. There was 
a significant difference between the three groups (F = 1.37, p = 0.0004) and a time versus group interaction (F = 4.30, p < 0.05). However, 
there was no difference between the vehicle- and asialoEPO-treated R6/2 mice at neither timepoints (Student's t-test, n. s.)
Age (weeks) wt R6/2 vehicle R6/2 + asialoEPO
n 756
10 66 ± 12 44 ± 14 20 ± 10
12 75 ± 7 11 ± 5 12 ± 7BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/17
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Reduced BrdU labeling in R6/2 mice, but no reversal by asialoEPO Figure 2
Reduced BrdU labeling in R6/2 mice, but no reversal by asialoEPO. All mice were injected with 50 mg/kg of BrdU i.p. 
every 12 h for their last six days of survival in order to assess whether asialoEPO would affect cell proliferation in the R6/2 
mice at the age of 12 weeks. The number of BrdU labeled cells was assessed by stereology in the subventricular zone in five 
striatal sections/mouse. In this region, there was only a trend towards a reduced number of BrdU labeled cells in R6/2 mice 
compared to their wild-type littermates (A; one factor ANOVA, F (2, 16) = 1.63, n.s.). In the dentate gyrus, BrdU labeled cells 
were assessed in 7–9 sections/mouse from the first anterior aspect of the structure, and the number was expressed as the 
average number per section (B). The data were analyzed using a one factor ANOVA (F (2, 16) = 23.50, p < 0.0001) that 
revealed a significant difference between the groups. In this region, we found that there was a reduced number of BrdU labeled 
cells in R6/2 mice compared to wild-type mice (Bonferroni-Dunn post-hoc test, p < 0.0001). However, the administration of 
asialoEPO was not able to reverse the reduced cell proliferation (Bonferroni-Dunn post-hoc test, p > 0.05).BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/17
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BrdU labeled cells in the dentate gyrus of the hippocampus Figure 3
BrdU labeled cells in the dentate gyrus of the hippocampus. Photomicrographs showing representative NeuN staining 
of the dentate gyrus in a wild-type (A), a vehicle-treated R6/2 (B) and an asialoEPO-treated R6/2 (C) mouse of 12 weeks of age. 
Photomicrographs showing representative BrdU labeling in adjacent sections of the dentate gyrus in a wild-type (D), a vehicle-
treated R6/2 (E) and an asialoEPO-treated R6/2 (F) mouse. Scale bar 100 µm.BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/17
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could both be stimulating in a similar fashion as enriched
environment, or stressful in a harmful way. Enriched envi-
ronment and stress have been shown to affect neurogene-
sis in opposite directions [40,48]. In order to investigate
to what extent neurogenesis is affected in R6/2 mice and
at what disease stage the change occurs, mice that are not
subjected to handling nor testing should be used. It will
then be important to consider whether the reduced BrdU
labeling is indeed due to a decreased number of prolifer-
ating cells or if it is a result of an increased death rate of
the proliferating cells. It may be that the turnover of neu-
rons is reduced in the R6/2 dentate gyrus, without affect-
ing the net number of neurons. In support of this is the
absence of a difference in total neuronal number in the
dentate gyrus between R6/2 and wild-type mice in this
study.
It is possible that altered neurogenesis is an important
pathological hallmark in HD. Recently it was reported
that there is an increased number of proliferating cells in
the subependymal layer adjacent to the striatum of HD
brains [49]. These cells were stained with the cell cycle
marker proliferating cell nuclear antigen (PCNA) and
50% of the cells were found to coexpress glial fibrilliary
acidic protein (GFAP) and only 5% expressed the neuro-
nal marker βIII-tubulin [49]. The neurogenesis in the den-
tate gyrus was never examined in the human HD brains.
However, the relationship between our data using BrdU
labeling and the published human data based on PCNA
immunohistochemistry is unclear at this point.
In this study, there was no effect of asialoEPO on the
reduced BrdU labeling in the R6/2 mice. There are only a
few studies on the role of EPO in neurogenesis in the lit-
erature today. It has been shown that EPO receptors are
important for normal brain development and that lack of
EPO receptors results in less neuronal progenitor cells
[50]. Interestingly, the effect of EPO may be region-
dependent as infusion of EPO into the lateral ventricles of
rats decreased the number of BrdU labeled cells in the
subventricular zone but had the opposite effect in the
olfactory bulb [30].
Conclusions
To summarize, the EPO analogue asialoEPO at the dosing
protocol used here, is ineffective in the R6/2 model of HD.
However, a definite conclusion regarding the lack of asia-
loEPO effects in R6/2 mice awaits future studies in the ret-
ina. Reduced hippocampal BrdU labeling in end-stage R6/
2 mice is a novel, and maybe, important neuropathologi-
cal feature in these mice. Future studies will shed light on
the significance of this alteration and may facilitate the
understanding of the pathological process in HD.
Methods
Transgenic animals and body weight measurements
Transgenic HD mice of the R6/2 line were originally pur-
chased from Jackson Laboratories (Bar Harbor, ME, USA)
and the colony was maintained by breeding heterozygous
R6/2 males with females from their background strain (F1
of CBA × C57Bl/6). Tails of the offspring were used to
obtain DNA for determination of the genotype using a
polymerase chain reaction assay [5]. The length of the
CAG repeat in our R6/2 colony was analyzed, and was
found to be stable at 142 ± 0.7 CAG repeats (n = 18, from
two different generations). The mice were housed in
groups with ad libitum access to food and water at a 12 h
light/dark cycle. The experimental procedures were
approved by the ethical committee at Lund University.
Mice were weighed once a week during the whole
experiment.
Administration of AsialoEPO
Mice from the same litters were divided into three groups
(n= 6–7 for each group). AsialoEPO was synthesized from
EPO exactly as described [28]. One group of R6/2 mice
was injected with 2.6 nmol/kg (80 µg/kg)
intraperitoneally (i.p.) in phosphate buffered saline (PBS)
three times per week, starting from 5 weeks of age until
they reached 12 weeks of age. Another group of R6/2 mice
and their wild-type littermates were injected (i.p.) with the
vehicle (PBS) following the same schedule.
Behavioral testing
Rotarod
Mice were trained on the rotarod for two days before the
testing began at 5 weeks of age. On the first training day
each mouse was placed on the rotarod for 120 s at a speed
of 5 rpm. On the second day, mice were given two sepa-
rate 120 s sessions at 10 rpm and one at 15 rpm. The mice
were tested on the following day with 3 trials at 15 rpm for
180 s each. The mean value of the latency to fall for these
3 trials was compared between the mice. Mice were tested
once a week using a similar block of 2 trials at ages 5, 6, 7,
8, 10, 11 and 12 weeks.
Paw clasping
At the same ages studied for the rotarod, mice were sub-
jected to the paw clasping test. To score the presence of
paw clasping, mice were suspended by the tail 10 cm
above the cage for 20 s. The paw clasping was scored from
zero to two points. Absence of paw clasping behavior or
only the front legs pressed together yielded zero points. If
mice pressed front paws to the stomach, one point was
given. If front paws touched hind legs, or both front and
hind legs pressed against the stomach, two points were
noted. All clasping tests were scored by an individual
blind to the genotype of the mice.BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/17
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Motor activity in an open field
The general motor activity was assessed in an open field.
The open field box was divided into 25 squares (5 × 5 cm
each). The mice were analyzed at 10 and 12 weeks. They
were allowed to habituate for 10 min and then their activ-
ity was recorded for the following 10 min. The number of
squares that the mice entered during the last 2 min of the
recording session was evaluated. This short time in the
end of the session was chosen in order to increase the
habituation period, when the activity is increased in nor-
mal animals due to their exploratory behavior. This
increase in activity is the greatest during the first 20 min in
a new environment [51].
BrdU injections
In order to assess the genesis of new cells in the brains, all
mice were injected with 50 mg/kg of the thymidine ana-
logue BrdU (in PBS, pH 7,2) i.p. every 12 h for their last
six days of survival. The mice were sacrificed 18 h after the
last BrdU injection.
Morphological analysis
At 12 weeks of age, all mice were deeply anesthetized with
pentobarbital and transcardially perfused with saline fol-
lowed by paraformaldehyde (4%) in 0.1 M PBS. The
brains were left in the fixative overnight and then dehy-
drated in 20% sucrose/0.1 M phosphate buffer. Coronal
sections were cut at four series throughout the brain on a
freezing microtome at a thickness of 40 µm and collected
in PBS. Free-floating sections were processed for NeuN
immunohistochemistry. Briefly, one series of sections was
quenched in 3% hydrogen peroxide/10% methanol in 0.1
M PBS for 15 min and then rinsed three times. The sec-
tions were preincubated for 1 h in 5% normal horse
serum (NHS) and 0.25% Triton X-100 in PBS and then
incubated overnight at room temperature with a primary
antibody against NeuN (diluted 1:1000, Chemicon,
Temecula, CA, USA) in PBS containing 2% NHS. After
incubation with a biotinylated horse anti-mouse antibody
(1: 200; Dakopatts, Copenhagen, Denmark) for 1 h, the
bound antibodies were visualized using an avidin-biotin-
peroxidase complex system (Vectastain ABC Elite Kit, Vec-
tor labs, Burlingame, CA, USA). To detect the presence of
huntingtin inclusions, the EM48 antibody was used at a
dilution of 1:500 (Chemicon). BrdU staining was
detected using a mouse anti-BrdU antibody (1:50; Dako,
Glostrup, Denmark). To visualize striatal neurons and the
outer anatomical borders of the striatum, the DARPP-32
antibody was used (1: 1000; Chemicon).
Cell counts and striatal volume assessments using 
stereology
All morphological analyses was performed on blind-
coded slides using an Olympus C.A.S.T.-Grid system
(Olympus Denmark A/S, Albertslund, Denmark) com-
posed of an Olympus BH2 microscope and an X-Y step
motor run by an IBM PC computer. The number of EM48-
immunopositive neurons in the striatum was assessed in
five sections from each striatum, using stereological prin-
ciples [52]. The level of these sections began at 2 sections
anterior to the appearance of the posterior anterior com-
missure. The number of BrdU-immunopositive cells in
the dentate gyrus was assessed in 7–9 sections/mouse
starting from the first anterior aspect of the structure, and
the number was expressed as the average number per sec-
tion. The total number of BrdU labeled cells in the sub-
ventricular zone (located adjacent to the ventricle in the
neostriatum) was assessed using stereology in five striatal
sections per mouse. Four mice from each group were ran-
domly selected and the striatal area was delineated in five
adjacent sections (in a 1:4 series) of the striatum proc-
essed for DARPP-32 immunohistochemistry. The level of
these sections began at 2 sections anterior to the appear-
ance of the posterior anterior commissure. The volume
was calculated, taking into account the frequency of sec-
tions (1:4) and their thickness (0.04 mm), according to
the Cavalieri principle [52]. Using the stereological equip-
ment, the surface area of 45 randomly selected DARPP-32
cell bodies/striatum was also assessed (15 neurons/sec-
tion in three sections/mouse). The number of NeuN-
immunopositive cells in the dentate gyrus was assessed in
the same mice using stereology (6 sections/mouse, start-
ing from the first anterior aspect of the structure).
Statistics
The data were analyzed with a one- or two-factor ANOVA
with repeated measures when appropriate, or un-paired
Student's t-tests, using the Statview 5.4 package (Abacus
concepts, Berkely, CA, USA). Data are presented as mean
± SEM. A p value of < 0.05 was considered significant.
List of abbreviations used
ANOVA analysis of variance
AsialoEPO asialoerythropoietin
BDNF brain-derived neurotrophic factor
BrdU bromodeoxyuridine
c-IAP2 cellular inhibitor of apoptosis proteins-2
CREB cAMP response element-binding protein
DARPP-32 dopamine and cAMP regulated phosphopro-
tein of a molecular weight of 32 kDa
EPO erythropoietin
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HD Huntington's disease
IGF1 insulin growth factor 1
Ip intraperitoneally
Jak2 Janus kinase 2
NeuN neuronal nuclei
NFkB nuclear factor-kB
NHS normal horse serum
NII neuronal intranuclear inclusions
PBS phosphate buffered saline
PCNA proliferating cell nuclear antigen
XIAP X-linked inhibitor of apoptosis proteins
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